Diligence memo · auto-generated · as of July 2, 2026

Checkpoint Surgical, LLC

Checkpoint Surgical, LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Checkpoint Surgical, LLC operates in Biotechnology, based in CLEVELAND.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Checkpoint Surgical, LLC has raised $9.2M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $7.5M on 2011-05-01.

Most recent recorded round closed around 2011-05-01.

Valuation (modeled)modeled

Provath models Checkpoint Surgical, LLC at approximately $270M (range $8.1M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.35× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era. Within the normal band (135% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 15.2 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 6.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 54% of Biotechnology peers (4293 compared).

Modeled value ranks above 75% of those peers.

Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.